MM&M12d
Novo Nordisk’s amycretin cuts weight by 22% in early obesity trial
Just over a month after its CagriSema readout disappointed analysts ... Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, which target ...
Investing15d
Viking Therapeutics stock gains traction with standout dual-agonist VK2735 efficacy data
Novo Nordisk reported that adults with obesity achieved significant weight loss using their semaglutide ... CagriSema. The maintained Buy rating and price target reflect a positive outlook for ...
Business Insider19d
Viking Therapeutics’ VK2735: A Promising Contender in the Weight-Loss Market with Superior Efficacy Profile
Pantginis emphasizes that VK2735, a dual GLP-1/GIP receptor agonist, may demonstrate superior weight loss outcomes compared to semaglutide ... s CagriSema trials present an opportunity for Viking ...
Investing15d
Viking Therapeutics stock gains traction with standout dual-agonist VK2735 efficacy data
Tuesday, Viking ... to semaglutide before the 72-week mark noted in Novo Nordisk's trial. Pantginis highlighted the potential of both the oral and subcutaneous forms of VK2735, especially when ...